HLHualin Helen Li

Hualin Helen Li

*This is an algorithmically generated author record based on publicly available information.

Hualin Helen Li has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dissecting the mechanism of action of the adjuvant system AS01 in human immune cells: synergy of QS-21 and monophosphoryl lipid A and role of type I interferons

    by Michelle Poe, Nickolas Neokosmidis, Juan F. Hernandez-Franco, Alyssa Q. Stiving, Emory M. Payne, Shailaa Kummar, Jian Xiong, Angela Wagner, David A. Foley, Daniel J. DiStefano, et al.

    The adjuvant system AS01 comprised of the TLR4 agonist monophosphoryl lipid A (MPLA) and the saponin QS-21 embedded in liposomes is currently used in recombinant vaccines against shingles, respiratory syncytial virus infection, and malaria. The efficacy of these vaccines is attributed to the strong immunostimulatory effect of AS01. While preclinical studies have shed light on the mechanisms by which AS01 enhances immune responses, few studies have been conducted with human immune cells to dissect how the two immunostimulants work individually and in combination. We investigated the effect of AS01 on human THP-1 cells and peripheral blood mononuclear cells (PBMCs) and found that it induced secretion of a broad panel of chemokines and a modest number of cytokines. Among the chemokines, CCL3 and CCL4 were found to have the greatest fold increase. Inhibition of TLR4 signaling revealed variable dependence on TLR4, while experiments with liposomes formulated with a TLR4 agonist, QS-21, or both demonstrated synergistic effects on the induction of many chemokines and TNF. AS01 induced strong expression of interferon-stimulated genes; this was greatly reduced by treatment with an antibody that blocks the type I interferon (IFN) receptor, indicating that AS01 induced a type I IFN-associated transcriptional signature that is partially dependent on signaling via the type I IFN receptor. AS01 selectively increased the expression of CD83 on THP-1 cells and this effect was found to be mostly driven by QS-21. This work provides novel insights into the mechanisms by which AS01 stimulates human immune cells.

  • Interference of target protein translation in multivalent mRNA vaccine in cell-based assay

    by Alyssa Q. Stiving, Geethanjali Dornadula, Benjamin W. Roose, Ariel Gonzalez, Melissa C. Whiteman, Hillary A. Schuessler, Hualin Helen Li, Xuanwen Li

  • Open Access

    Cell-Based Relative Potency of a Respiratory Syncytial Virus mRNA Vaccine Correlates with In Vivo Immunogenicity

    by Katrina Feller, Hesham Nawar, Liping Song, Amanda Abrams, Liang Shang, Ashley Gruber, Tatyana Yun, Hualin Helen Li

    Background/Objectives: Potency is a critical quality attribute for vaccine development as well as clinical drug product (DP) lot release and stability testing. Animal studies have the potential to offer conclusive insights about the potency of vaccines by demonstrating technical relevance with respect to the hypothesized vaccine mode of action. However, animal studies are expensive, time-consuming, labor intensive, and, most importantly, involve the use of animals. Therefore, alternative in vitro potency assays should be explored. Methods: In this study, female BALB/c mice were immunized intramuscularly with various doses of a respiratory syncytial virus (RSV) mRNA vaccine V171 lots at day 0 and day 21. Vaccine-elicited immune responses were determined by ELISA (post-dose 1) and neutralizing assay (post-dose 2). These vaccine lots were also tested in a cell-based relative potency assay in which the ability of each lot to express the RSV F protein in Hep G2 cells was measured against a reference standard. Results: Effective Dose 50s (ED50s) of the vaccine lots were determined with probit models based on dichotomized ELISA or neutralizing titers. Statistical analysis demonstrated that the post-dose 2 neutralizing ED50 correlates with cell-based relative potency (Pearson’s correlation test ln (RP) and ln (ED50): correlation coefficient = −0.82; p-value = 0.047). Conclusions: These data merit the use of a cell-based potency assay to replace the animal study to support V171 vaccine development and to use for DP lot release and stability testing. This study also establishes proof-of-concept of using cell-based potency assays as an alternative to animal immunogenicity studies for mRNA-based vaccines.


  • Development and qualification of cell-based relative potency assay for a human respiratory syncytial virus (RSV) mRNA vaccine

    by Hualin Helen Li, Jenny Xu, Li He, Lynne Ireland Denny, Richard R. Rustandi, Geethanjali Dornadula, Brock Fiorito, Zhi-Qiang Zhang


  • Novel adjuvants enhance immune responses elicited by a replication-defective human cytomegalovirus vaccine in nonhuman primates

    by Hualin Li, Morgan A. Monslow, Daniel C. Freed, Dan Chang, Fengsheng Li, Marian Gindy, Dai Wang, Kalpit Vora, Amy S. Espeseth, Nikolai Petrovsky, et al.


  • Open Access

    Human monoclonal antibodies isolated from a primary pneumococcal conjugate Vaccinee demonstrates the expansion of an antigen-driven Hypermutated memory B cell response

    by Zhifeng Chen, Kara S. Cox, Aimin Tang, Jeanette Roman, Malorie Fink, Robin M. Kaufhold, Liming Guan, Andy Xie, Melissa A. Boddicker, Debra Mcguinness, et al.

    Community-acquired pneumonia is a leading infectious cause of hospitalization. A few vaccines exist to prevent pneumococcal disease in adults, including a pneumococcal polysaccharide unconjugated vaccine and a protein conjugated polysaccharide vaccine. Previous studies on the human immune response to the unconjugated vaccine showed that the vaccine boosted the existing memory B cells. In the present study, we investigated the human B cell immune response following pneumococcal polysaccharide conjugate vaccination. Plasmablast B cells from a pneumococcal polysaccharide conjugate vaccinee were isolated and cloned for analysis. In response to primary vaccination, identical sequences from the plasmablast-derived antibodies were identified from multiple B cells, demonstrating evidence of clonal expansion. We evaluated the binding specificity of these human monoclonal antibodies in immunoassays, and tested there in vitro function in a multiplexed opsonophagocytic assay (MOPA). To characterize the plasmablast B cell response to the pneumococcal conjugated vaccine, the germline usage and the variable region somatic hypermutations on these antibodies were analyzed. Furthermore, a serotype 4 polysaccharide-specific antibody was tested in an animal challenge study to explore the in vivo functional activity. The data suggests that the pneumococcal polysaccharide conjugate vaccine boosted memory B cell responses, likely derived from previous pneumococcal exposure. The majority of the plasmablast-derived antibodies contained higher numbers of variable region somatic hypermutations and evidence for selection, as demonstrated by replacement to silent ratio’s (R/S) greater than 2.9 in the complementarity-determining regions (CDRs). In addition, we found that VH3/JH4 was the predominant germline sequence used in these polysaccharide-specific B cells. All of the tested antibodies demonstrated narrow polysaccharide specificity in ELISA binding, and demonstrated functional opsonophagocytic killing (OPK) activity in the MOPA assay. The in-vivo animal challenge study showed that the tested serotype 4 polysaccharide-specific antibody demonstrated a potent protective effect when administered prior to bacterial challenge. The findings on the pneumococcal polysaccharide conjugate vaccine responses from a vaccinated subject reported in this study are similar to previously published data on the pneumococcal polysaccharide unconjugated vaccine responses. In both vaccine regimens, the pre-existing human memory B cells were expanded after vaccination with preferential use of the germline VH3/JH4 genes.


  • Open Access

    Respiratory syncytial virus elicits enriched CD8+ T lymphocyte responses in lung compared with blood in African green monkeys

    by Hualin Li, Cheryl Callahan, Michael Citron, Zhiyun Wen, Sinoeun Touch, Morgan A. Monslow, Kara S. Cox, Daniel J. DiStefano, Kalpit A. Vora, Andrew Bett, et al.

    Respiratory syncytial virus (RSV) is a leading cause of serious lower respiratory tract disease in young children and older adults throughout the world. Prevention of severe RSV disease through active immunization is optimal but no RSV vaccine has been licensed so far. Immune mechanisms of protection against RSV infection in humans have not been fully established, thus a comprehensive characterization of virus-specific immune responses in a relevant animal model will be beneficial in defining correlates of protection. In this study, we infected juvenile naive AGMs with RSV A2 strain and longitudinally assessed virus-specific humoral and cellular immune responses in both peripheral blood and the respiratory tract. RSV viral loads at nasopharyngeal surfaces and in the lung peaked at around day 5 following infection, and then largely resolved by day 10. Low levels of neutralizing antibody titers were detected in serum, with similar kinetics as RSV fusion (F) protein-binding IgG antibodies. RSV infection induced CD8+, but very little CD4+, T lymphocyte responses in peripheral blood. Virus-specific CD8+ T cell frequencies were ~10 fold higher in bronchoaveolar lavage (BAL) compared to peripheral blood and exhibited effector memory (CD95+CD28-) / tissue resident memory (CD69+CD103+) T (TRM) cell phenotypes. The kinetics of virus-specific CD8+ T cells emerging in peripheral blood and BAL correlated with declining viral titers, suggesting that virus-specific cellular responses contribute to the clearance of RSV infection. RSV-experienced AGMs were protected from subsequent exposure to RSV infection. Additional studies are underway to understand protective correlates in these seropositive monkeys.